Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors

Pommier, 2009, DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition, Chem. Rev., 109, 2894, 10.1021/cr900097c Wang, 2002, Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell Biol., 3, 430, 10.1038/nrm831 Champoux, 2001, DNA topoisomerases: structure, function, and mechanism, Annu. Rev. Biochem., 70, 369, 10.1146/annurev.biochem.70.1.369 Zhang, 2001, Human mitochondrial topoisomerase I, Proc. Natl. Acad. Sci. U. S. A., 98, 10608, 10.1073/pnas.191321998 Nitiss, 2009, Targeting DNA topoisomerase II in cancer chemotherapy, Nat. Rev. Cancer, 9, 338, 10.1038/nrc2607 Nitiss, 2009, DNA topoisomerase II and its growing repertoire of biological functions, Nat. Rev. Cancer, 9, 327, 10.1038/nrc2608 Wang, 1998, Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine, Q. Rev. Biophys., 31, 107, 10.1017/S0033583598003424 Pommier, 2006, Topoisomerase I inhibitors: camptothecins and beyond, Nat. Rev. Cancer, 6, 789, 10.1038/nrc1977 Pommier, 1999, Topoisomerase I inhibitors: selectivity and cellular resistance, Drug Resist. Updat., 2, 307, 10.1054/drup.1999.0102 Wang, 1971, Interaction between DNA and an Escherichia coli protein omega, J. Mol. Biol., 55, 523, 10.1016/0022-2836(71)90334-2 D'Arpa, 1988, cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment, Proc. Natl. Acad. Sci. U. S. A., 85, 2543, 10.1073/pnas.85.8.2543 Wang, 1996, An RNA topoisomerase, Proc. Natl. Acad. Sci. U. S. A., 93, 9477, 10.1073/pnas.93.18.9477 Leppard, 2005, Human DNA topoisomerase I: relaxation, roles, and damage control, Chromosoma, 114, 75, 10.1007/s00412-005-0345-5 Stivers, 1997, Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation, Biochemistry, 36, 5212, 10.1021/bi962880t Stewart, 1998, A model for the mechanism of human topoisomerase I, Science, 279, 1534, 10.1126/science.279.5356.1534 Koster, 2005, Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB, Nature, 434, 671, 10.1038/nature03395 Alsner, 1992, Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function, J. Biol. Chem., 267, 12408, 10.1016/S0021-9258(18)42288-0 Baker, 1995, Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy, Cytometry, 19, 134, 10.1002/cyto.990190208 Husain, 1994, Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy, Cancer Res., 54, 539 Kellner, 1997, Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies, J. Histochem. Cytochem., 45, 251, 10.1177/002215549704500210 Morham, 1996, Targeted disruption of the mouse topoisomerase I gene by camptothecin selection, Mol. Cell. Biol., 16, 6804, 10.1128/MCB.16.12.6804 Zhang, 2000, Essential functions of DNA topoisomerase I in Drosophila melanogaster, Dev. Biol., 222, 27, 10.1006/dbio.2000.9704 Thrash, 1984, Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity, J. Biol. Chem., 259, 1375, 10.1016/S0021-9258(17)43412-0 Uemura, 1986, The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases, EMBO J., 5, 2355, 10.1002/j.1460-2075.1986.tb04504.x Eng, 1988, Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin, Mol. Pharmacol., 34, 755 Wall, 1966, Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, J. Am. Chem. Soc., 88, 3888, 10.1021/ja00968a057 Horwitz, 1971, Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin, Biochem. Biophys. Res. Commun., 45, 723, 10.1016/0006-291X(71)90476-1 Kessel, 1971, Effects of camptothecin on RNA synthesis in leukemia L1210 cells, Biochim. Biophys. Acta, 246, 225, 10.1016/0005-2787(71)90131-6 Kessel, 1972, Camptothecin effects on DNA synthesis in murine leukemia cells, Biochim. Biophys. Acta, 269, 210, 10.1016/0005-2787(72)90429-7 Spataro, 1972, Studies on camptothecin-induced degradation and apparent reaggregation of DNA from L1210 cells, Biochem. Biophys. Res. Commun., 48, 643, 10.1016/0006-291X(72)90396-8 Hsiang, 1985, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I, J. Biol. Chem., 260, 14873, 10.1016/S0021-9258(17)38654-4 Nitiss, 1988, DNA topoisomerase-targeting antitumor drugs can be studied in yeast, Proc. Natl. Acad. Sci. U. S. A., 85, 7501, 10.1073/pnas.85.20.7501 Pommier, 2006, Repair of topoisomerase I-mediated DNA damage, Prog. Nucleic Acid Res. Mol. Biol., 81, 179, 10.1016/S0079-6603(06)81005-6 Burke, 1994, The structural basis of camptothecin interactions with human serum albumin: impact on drug stability, J. Med. Chem., 37, 40, 10.1021/jm00027a005 Teicher, 2008, Next generation topoisomerase I inhibitors: rationale and biomarker strategies, Biochem. Pharmacol., 75, 1262, 10.1016/j.bcp.2007.10.016 Urasaki, 2001, Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site, Cancer Res., 61, 504 Kurtzberg, 2008, Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors, Mol. Cancer Ther., 7, 3212, 10.1158/1535-7163.MCT-08-0568 Antony, 2005, Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison, Mol. Pharmacol., 67, 523, 10.1124/mol.104.003889 Antony, 2007, Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance, Cancer Res., 67, 10397, 10.1158/0008-5472.CAN-07-0938 Miao, 2007, Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses, Cancer Res., 67, 8752, 10.1158/0008-5472.CAN-06-4554 Covey, 1989, Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I, Cancer Res., 49, 5016 Jaxel, 1991, Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin, J. Biol. Chem., 266, 20418, 10.1016/S0021-9258(18)54939-5 Leteurtre, 1993, Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm, Biochemistry, 32, 8955, 10.1021/bi00085a029 Tanizawa, 1995, Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives, Biochemistry, 34, 7200, 10.1021/bi00021a035 Pourquier, 1997, Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects, J. Biol. Chem., 272, 26441, 10.1074/jbc.272.42.26441 Pourquier, 1997, Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I, J. Biol. Chem., 272, 7792, 10.1074/jbc.272.12.7792 Strumberg, 2000, Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff, Mol. Cell. Biol., 20, 3977, 10.1128/MCB.20.11.3977-3987.2000 Furuta, 2003, Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes, J. Biol. Chem., 278, 20303, 10.1074/jbc.M300198200 Sordet, 2003, Apoptosis induced by topoisomerase inhibitors, Curr. Med. Chem. Anticancer Agents, 3, 271, 10.2174/1568011033482378 Huang, 2010, Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage, Cell Res., 20, 1060, 10.1038/cr.2010.95 Lin, 2008, A ubiquitin-proteasome pathway for the repair of topoisomerase I–DNA covalent complexes, J. Biol. Chem., 283, 21074, 10.1074/jbc.M803493200 Sordet, 2009, Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks, EMBO Rep., 10, 887, 10.1038/embor.2009.97 Hertzberg, 1989, On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme–DNA complex, Biochemistry, 28, 4629, 10.1021/bi00437a018 Merino, 1993, DNA topoisomerase I is involved in both repression and activation of transcription, Nature, 365, 227, 10.1038/365227a0 Darzynkiewicz, 1996, The cell cycle effects of camptothecin, Ann. N. Y. Acad. Sci., 803, 93, 10.1111/j.1749-6632.1996.tb26379.x Pommier, 1998, Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme, Biochim. Biophys. Acta, 1400, 83, 10.1016/S0167-4781(98)00129-8 Khobta, 2006, Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells, J. Mol. Biol., 357, 127, 10.1016/j.jmb.2005.12.069 Capranico, 2007, The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I, Biochimie, 89, 482, 10.1016/j.biochi.2007.01.001 Sordet, 2008, Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I, J. Mol. Biol., 381, 540, 10.1016/j.jmb.2008.06.028 Desai, 2003, Transcription-dependent degradation of topoisomerase I–DNA covalent complexes, Mol. Cell. Biol., 23, 2341, 10.1128/MCB.23.7.2341-2350.2003 Ljungman, 2004, Transcription — guarding the genome by sensing DNA damage, Nat. Rev. Cancer, 4, 727, 10.1038/nrc1435 Holm, 1989, Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells, Cancer Res., 49, 6365 Hsiang, 1989, DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues, Cancer Res., 49, 4385 Morris, 1996, Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase—I: evidence for cell cycle-independent toxicity, J. Cell Biol., 134, 757, 10.1083/jcb.134.3.757 Goldwasser, 1996, Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells, Cancer Res., 56, 4430 Nitiss, 1996, Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA, Mol. Pharmacol., 50, 1095 Zhou, 2002, Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects, Cancer Res., 62, 1688 Madden, 1992, Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin, Cancer Res., 52, 525 Burgess, 2008, Topoisomerase levels determine chemotherapy response in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 105, 9053, 10.1073/pnas.0803513105 Liao, 2008, Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan, Mol. Pharmacol., 73, 490, 10.1124/mol.107.041178 McLeod, 1996, Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity, Br. J. Cancer, 74, 508, 10.1038/bjc.1996.394 Arnaud, 2011, The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan, Eur. J. Cancer, 47, 640, 10.1016/j.ejca.2010.11.019 Kubota, 2011, ERas enhances resistance to CPT-11 in gastric cancer, Anticancer. Res., 31, 3353 Guo, 2010, Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2), J. Pharm. Pharmacol., 62, 973, 10.1111/j.2042-7158.2010.01128.x Zander, 2010, Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan, Cancer Res., 70, 1700, 10.1158/0008-5472.CAN-09-3367 Rasheed, 2003, Mechanisms of resistance to topoisomerase I-targeting drugs, Oncogene, 22, 7296, 10.1038/sj.onc.1206935 Beidler, 1995, Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity, Mol. Pharmacol., 47, 907 Desai, 1997, Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin, J. Biol. Chem., 272, 24159, 10.1074/jbc.272.39.24159 Zhang, 2004, Cullin 3 promotes proteasomal degradation of the topoisomerase I–DNA covalent complex, Cancer Res., 64, 1114, 10.1158/0008-5472.CAN-03-2858 Kerzendorfer, 2010, Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks, Hum. Mol. Genet., 19, 1324, 10.1093/hmg/ddq008 Cusack, 2001, Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition, Cancer Res., 61, 3535 Mao, 2000, SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage, Proc. Natl. Acad. Sci. U. S. A., 97, 4046, 10.1073/pnas.080536597 Muller, 2001, SUMO, ubiquitin's mysterious cousin, Nat. Rev. Mol. Cell Biol., 2, 202, 10.1038/35056591 Mao, 2002, Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status, Proc. Natl. Acad. Sci. U. S. A., 99, 1235, 10.1073/pnas.022631899 Rallabhandi, 2002, Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin, J. Biol. Chem., 277, 40020, 10.1074/jbc.M200388200 Desai, 2001, Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells, Cancer Res., 61, 5926 Squires, 1993, Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA, Cancer Res., 53, 2012 El-Khamisy, 2009, Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin, DNA Repair (Amst), 8, 760, 10.1016/j.dnarep.2009.02.002 Hudson, 2012, SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair, Nat. Commun., 3, 733, 10.1038/ncomms1739 Das, 2009, Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA–PK, EMBO J., 28, 3667, 10.1038/emboj.2009.302 Chiang, 2010, TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage, Cell Cycle, 9, 588, 10.4161/cc.9.3.10598 El-Khamisy, 2005, Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1, Nature, 434, 108, 10.1038/nature03314 Date, 2001, Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene, Nat. Genet., 29, 184, 10.1038/ng1001-184 Moreira, 2001, Homozygosity mapping of Portuguese and Japanese forms of ataxia-oculomotor apraxia to 9p13, and evidence for genetic heterogeneity, Am. J. Hum. Genet., 68, 501, 10.1086/318191 Caldecott, 2008, Single-strand break repair and genetic disease, Nat. Rev. Genet., 9, 619, 10.1038/nrg2380 Gueven, 2004, Aprataxin, a novel protein that protects against genotoxic stress, Hum. Mol. Genet., 13, 1081, 10.1093/hmg/ddh122 Christmann, 2008, WRN protects against topo I but not topo II inhibitors by preventing DNA break formation, DNA Repair (Amst), 7, 1999, 10.1016/j.dnarep.2008.08.008 Tomicic, 2005, Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival, Cancer Res., 65, 8920, 10.1158/0008-5472.CAN-05-0266 Sakasai, 2010, Proteasome inhibition suppresses DNA-dependent protein kinase activation caused by camptothecin, DNA Repair (Amst), 9, 76, 10.1016/j.dnarep.2009.10.008 Lin, 2009, Proteasome-dependent processing of topoisomerase I–DNA adducts into DNA double strand breaks at arrested replication forks, J. Biol. Chem., 284, 28084, 10.1074/jbc.M109.030601 Tomicic, 2010, Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage, J. Pharmacol. Exp. Ther., 332, 316, 10.1124/jpet.109.159962 Zhang, 2011, Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells, Nucleic Acids Res., 39, 3607, 10.1093/nar/gkq1304 Regairaz, 2011, Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I–DNA complexes, J. Cell Biol., 195, 739, 10.1083/jcb.201104003 Ehmsen, 2009, A junction branch point adjacent to a DNA backbone nick directs substrate cleavage by Saccharomyces cerevisiae Mus81-Mms4, Nucleic Acids Res., 37, 2026, 10.1093/nar/gkp038 Vance, 2002, Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage, Proc. Natl. Acad. Sci. U. S. A., 99, 13669, 10.1073/pnas.202242599 Liu, 2004, The role of TDP1 from budding yeast in the repair of DNA damage, DNA Repair (Amst), 3, 593, 10.1016/j.dnarep.2004.03.030 Katyal, 2007, TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo, EMBO J., 26, 4720, 10.1038/sj.emboj.7601869 Hubert, 2011, Topoisomerase 1 and single-strand break repair modulate transcription-induced CAG repeat contraction in human cells, Mol. Cell. Biol., 31, 3105, 10.1128/MCB.05158-11 Plo, 2003, Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions, DNA Repair (Amst), 2, 1087, 10.1016/S1568-7864(03)00116-2 Zhou, 2005, Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl–DNA phosphodiesterase (TDP1), Nucleic Acids Res., 33, 289, 10.1093/nar/gki170 Interthal, 2005, Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages, J. Biol. Chem., 280, 36518, 10.1074/jbc.M508898200 Interthal, 2005, SCAN1 mutant Tdp1 accumulates the enzyme–DNA intermediate and causes camptothecin hypersensitivity, EMBO J., 24, 2224, 10.1038/sj.emboj.7600694 Miao, 2006, Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes, DNA Repair (Amst), 5, 1489, 10.1016/j.dnarep.2006.07.004 Perego, 2012, Role of tyrosyl–DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition, Biochem. Pharmacol., 83, 27, 10.1016/j.bcp.2011.09.021 Gupta, 1998, Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy, Cancer Ther., 1, 292 Rubin, 1995, A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin, Clin. Cancer Res., 1, 269 Saleem, 2000, Mechanisms of resistance to camptothecins, Ann. N. Y. Acad. Sci., 922, 46, 10.1111/j.1749-6632.2000.tb07024.x Lenz, 2003, Clinical update: proteasome inhibitors in solid tumors, Cancer Treat Rev., 29, 41, 10.1016/S0305-7372(03)00082-3 Shao, 1999, Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA–PK complexes, EMBO J., 18, 1397, 10.1093/emboj/18.5.1397 Tian, 2007, The relationship between the down-regulation of DNA–PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa, Oncol. Rep., 18, 927 Darroudi, 2007, Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle, Mutat. Res., 615, 111, 10.1016/j.mrfmmm.2006.11.029 Katsube, 2011, Differences in sensitivity to DNA-damaging agents between XRCC4- and Artemis-deficient human cells, J. Radiat. Res., 52, 415, 10.1269/jrr.10168 Biard, 2007, Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones, Nucleic Acids Res., 35, 3535, 10.1093/nar/gkm195 Yaneva, 2005, Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor, Nucleic Acids Res., 33, 5320, 10.1093/nar/gki821 Adachi, 2004, Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage, J. Biol. Chem., 279, 37343, 10.1074/jbc.M313910200 Otsuki, 2007, WRN counteracts the NHEJ pathway upon camptothecin exposure, Biochem. Biophys. Res. Commun., 355, 477, 10.1016/j.bbrc.2007.01.175 Xiao, 2003, Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents, J. Biol. Chem., 278, 21767, 10.1074/jbc.M300229200 Yin, 2002, Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350, Biochem. Biophys. Res. Commun., 295, 435, 10.1016/S0006-291X(02)00683-6 Cliby, 2002, S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function, J. Biol. Chem., 277, 1599, 10.1074/jbc.M106287200 Hapke, 2002, Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38, Int. J. Oncol., 21, 1059 Flatten, 2005, The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons, J. Biol. Chem., 280, 14349, 10.1074/jbc.M411890200 Wang, 2002, CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity, Cell Cycle, 1, 267, 10.4161/cc.1.4.137 Shao, 1997, Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function, Cancer Res., 57, 4029 Xiao, 2005, A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation, Oncogene, 24, 1403, 10.1038/sj.onc.1208309 Schwarz, 2003, Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation, Mol. Cancer Res., 1, 598 Chaturvedi, 1999, Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway, Oncogene, 18, 4047, 10.1038/sj.onc.1202925 Ward, 2001, Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress, J. Biol. Chem., 276, 47759, 10.1074/jbc.C100569200 Zuco, 2010, ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968, Cancer Lett., 292, 186, 10.1016/j.canlet.2009.12.001 Agner, 2005, Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway, Exp. Cell Res., 302, 162, 10.1016/j.yexcr.2004.08.035 Smith, 1989, Enhanced sensitivity to camptothecin in ataxia—telangiectasia cells and its relationship with the expression of DNA topoisomerase I, Int. J. Radiat. Biol., 55, 217, 10.1080/09553008914550271 Jones, 1993, Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells, Carcinogenesis, 14, 2487, 10.1093/carcin/14.12.2487 Johnson, 1999, Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxia-telangiectasia cells, Biochem. Biophys. Res. Commun., 261, 317, 10.1006/bbrc.1999.1024 Johnson, 2000, Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group, Mutagenesis, 15, 367, 10.1093/mutage/15.4.367 Reaper, 2011, Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR, Nat. Chem. Biol., 7, 428, 10.1038/nchembio.573 O'Driscoll, 2007, Cellular and clinical impact of haploinsufficiency for genes involved in ATR signaling, Am. J. Hum. Genet., 81, 77, 10.1086/518696 O'Driscoll, 2009, Mouse models for ATR deficiency, DNA Repair (Amst), 8, 1333, 10.1016/j.dnarep.2009.09.001 Nghiem, 2001, ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation, Proc. Natl. Acad. Sci. U. S. A., 98, 9092, 10.1073/pnas.161281798 Cortez, 2001, ATR and ATRIP: partners in checkpoint signaling, Science, 294, 1713, 10.1126/science.1065521 Wilsker, 2007, Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival, Mol. Cancer Ther., 6, 1406, 10.1158/1535-7163.MCT-06-0679 Flatt, 2000, p53 regulation of G(2) checkpoint is retinoblastoma protein dependent, Mol. Cell. Biol., 20, 4210, 10.1128/MCB.20.12.4210-4223.2000 Magrini, 2002, Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status, Int. J. Cancer, 101, 23, 10.1002/ijc.10565 Wang, 2004, p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition, Oncogene, 23, 1283, 10.1038/sj.onc.1207244 Furuta, 2006, p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine, Oncogene, 25, 2839, 10.1038/sj.onc.1209313 Chang, 1999, A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents, Cancer Res., 59, 3761 te Poele, 2002, DNA damage is able to induce senescence in tumor cells in vitro and in vivo, Cancer Res., 62, 1876 Schmitt, 2002, A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy, Cell, 109, 335, 10.1016/S0092-8674(02)00734-1 Bhonde, 2006, Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth, Oncogene, 25, 165, 10.1038/sj.onc.1209017 Andreassen, 2001, Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1, Mol. Biol. Cell, 12, 1315, 10.1091/mbc.12.5.1315 Bhonde, 2006, DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis, J. Biol. Chem., 281, 8675, 10.1074/jbc.M511333200 Morandi, 2008, Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines, Mol. Cancer, 7, 66, 10.1186/1476-4598-7-66 Slichenmyer, 1993, Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage, Cancer Res., 53, 4164 Weller, 1998, Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses, Int. J. Cancer, 79, 640, 10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-Z Brown, 1999, Apoptosis, p53, and tumor cell sensitivity to anticancer agents, Cancer Res., 59, 1391 Nieves-Neira, 1999, Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways, Int. J. Cancer, 82, 396, 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z McDonald, 1998, Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors, Br. J. Cancer, 78, 745, 10.1038/bjc.1998.571 Schmidt, 2001, Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage, Eur. J. Pharmacol., 412, 21, 10.1016/S0014-2999(00)00923-7 Gobert, 1996, Modulation of DNA topoisomerase I activity by p53, Biochemistry, 35, 5778, 10.1021/bi952327w Soe, 2003, p53 stimulates human topoisomerase I activity by modulating its DNA binding, Nucleic Acids Res., 31, 6585, 10.1093/nar/gkg846 Stephan, 2002, Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro, Nucleic Acids Res., 30, 5087, 10.1093/nar/gkf659 Winter, 1998, Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression, J. Pharmacol. Exp. Ther., 286, 1374 Dubrez, 1995, The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors, Leukemia, 9, 1013 Solary, 1996, Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors, Bull. Cancer, 83, 205 Shimizu, 1997, Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases, Leukemia, 11, 1238, 10.1038/sj.leu.2400734 Gupta, 1997, Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells, Clin. Cancer Res., 3, 1653 Blumenthal, 2004, An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression, Int. J. Cancer, 108, 293, 10.1002/ijc.11534 Davis, 1998, Complex response of breast epithelial cell lines to topoisomerase inhibitors, Anticancer. Res., 18, 2919 te Poele, 1999, Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines, Br. J. Cancer, 81, 1285, 10.1038/sj.bjc.6694370 Abal, 2004, Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line, Oncogene, 23, 1737, 10.1038/sj.onc.1207299 Oggionni, 2005, p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma, Oncology, 69, 154, 10.1159/000087839 Daoud, 2003, Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study, Cancer Res., 63, 2782 Roos, 2006, DNA damage-induced cell death by apoptosis, Trends Mol. Med., 12, 440, 10.1016/j.molmed.2006.07.007 Kaufmann, 2012, Fas death receptor signalling: roles of Bid and XIAP, Cell Death Differ., 19, 42, 10.1038/cdd.2011.121 Ciusani, 2002, Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors, Biochem. Pharmacol., 63, 881, 10.1016/S0006-2952(01)00837-1 Ferreira, 2000, Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460, Cancer Res., 60, 7133 Ferreira, 2000, Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway, Clin. Cancer Res., 6, 203 Dejosez, 2000, Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan, Cell Death Differ., 7, 1127, 10.1038/sj.cdd.4400746 Song, 2003, TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways, Brain Pathol., 13, 539, 10.1111/j.1750-3639.2003.tb00484.x Wang, 2003, Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy, Proc. Natl. Acad. Sci. U. S. A., 100, 15095, 10.1073/pnas.2435285100 Monks, 2000, UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines, Invest. New Drugs, 18, 95, 10.1023/A:1006313611677 Deveraux, 1997, X-linked IAP is a direct inhibitor of cell-death proteases, Nature, 388, 300, 10.1038/40901 Deveraux, 1998, IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases, EMBO J., 17, 2215, 10.1093/emboj/17.8.2215 Galvan, 2004, Interaction of checkpoint kinase 1 and the X-linked inhibitor of apoptosis during mitosis, FEBS Lett., 558, 57, 10.1016/S0014-5793(03)01488-1 Jin, 2009, cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation, Cancer Res., 69, 1782, 10.1158/0008-5472.CAN-08-2256 Wu, 2010, ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress, Mol. Cell, 40, 75, 10.1016/j.molcel.2010.09.010 Bruno, 2008, Che-1 activates XIAP expression in response to DNA damage, Cell Death Differ., 15, 515, 10.1038/sj.cdd.4402284 Bruno, 2006, Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint, Cancer Cell, 10, 473, 10.1016/j.ccr.2006.10.012 Li, 1998, Control of apoptosis and mitotic spindle checkpoint by survivin, Nature, 396, 580, 10.1038/25141 Salvesen, 2002, IAP proteins: blocking the road to death's door, Nat. Rev. Mol. Cell Biol., 3, 401, 10.1038/nrm830 Kanwar, 2011, Targeting survivin in cancer: the cell-signalling perspective, Drug Discov. Today, 16, 485, 10.1016/j.drudis.2011.04.001 Shin, 2001, An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and ‐7, Biochemistry, 40, 1117, 10.1021/bi001603q Arora, 2007, Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)–XAF1 complex, J. Biol. Chem., 282, 26202, 10.1074/jbc.M700776200 Liu, 2004, Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells, Oncogene, 23, 39, 10.1038/sj.onc.1206978 Uren, 2000, Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype, Curr. Biol., 10, 1319, 10.1016/S0960-9822(00)00769-7 Altieri, 2008, Survivin, cancer networks and pathway-directed drug discovery, Nat. Rev. Cancer, 8, 61, 10.1038/nrc2293 Skoufias, 2000, Human survivin is a kinetochore-associated passenger protein, J. Cell Biol., 151, 1575, 10.1083/jcb.151.7.1575 Lens, 2003, Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension, EMBO J., 22, 2934, 10.1093/emboj/cdg307 Yang, 2004, Cell division and cell survival in the absence of survivin, Proc. Natl. Acad. Sci. U. S. A., 101, 15100, 10.1073/pnas.0406665101 Castedo, 2004, Cell death by mitotic catastrophe: a molecular definition, Oncogene, 23, 2825, 10.1038/sj.onc.1207528 Yamamoto, 2008, Cancer cells survive with survivin, Cancer Sci., 99, 1709, 10.1111/j.1349-7006.2008.00870.x Borgne, 2006, Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment, Oncogene, 25, 7361, 10.1038/sj.onc.1209718 Tse, 2004, Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe, Cancer Res., 64, 6635, 10.1158/0008-5472.CAN-04-0841 Vogel, 2005, The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy, J. Biol. Chem., 280, 4025, 10.1074/jbc.C400545200 Vogel, 2007, Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation, Cancer Res., 67, 339, 10.1158/0008-5472.CAN-06-2548 Reichert, 2011, Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma, Radiother. Oncol., 101, 51, 10.1016/j.radonc.2011.06.037 Lladser, 2011, Is survivin the potential Achilles' heel of cancer?, Adv. Cancer Res., 111, 1, 10.1016/B978-0-12-385524-4.00001-5 Sato, 2007, Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake, Int. J. Oncol., 30, 695 Sato, 2008, Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan, Int. J. Oncol., 32, 171 Pennati, 2004, Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo, Carcinogenesis, 25, 1129, 10.1093/carcin/bgh107 Griffith, 2003, The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis, Cancer Chemother. Pharmacol., 52, 175, 10.1007/s00280-003-0656-2 Ravi, 2004, Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL, Cancer Res., 64, 9105, 10.1158/0008-5472.CAN-04-2488 Mizutani, 2006, Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells, Exp. Oncol., 28, 209 Zhang, 2008, CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901, Invest. New Drugs, 26, 517, 10.1007/s10637-008-9120-9 Li, 2009, Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms, Anticancer Drugs, 20, 770, 10.1097/CAD.0b013e32832fe472 Tun, 2007, Activation of the extrinsic caspase pathway in cultured cortical neurons requires p53-mediated down-regulation of the X-linked inhibitor of apoptosis protein to induce apoptosis, J. Neurochem., 102, 1206, 10.1111/j.1471-4159.2007.04609.x Yamaguchi, 2005, Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death, Oncol. Rep., 14, 1311 Bevins, 2005, It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells, Cancer Res., 65, 6957, 10.1158/0008-5472.CAN-05-0836 Arnt, 2002, Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ, J. Biol. Chem., 277, 44236, 10.1074/jbc.M207578200 Minderman, 2005, In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells, Mol. Cancer Ther., 4, 885, 10.1158/1535-7163.MCT-04-0048 Takigawa, 2006, Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms, Anticancer. Res., 26, 1869 Liston, 2001, Identification of XAF1 as an antagonist of XIAP anti-Caspase activity, Nat. Cell Biol., 3, 128, 10.1038/35055027 Plenchette, 2007, The role of XAF1 in cancer, Curr. Opin. Investig. Drugs, 8, 469 Dohi, 2004, An IAP-IAP complex inhibits apoptosis, J. Biol. Chem., 279, 34087, 10.1074/jbc.C400236200 Zhang, 2010, Identification of a functional p53 responsive element within the promoter of XAF1 gene in gastrointestinal cancer cells, Int. J. Oncol., 36, 1031 Zou, 2012, XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification, Mol. Carcinog., 51, 422, 10.1002/mc.20807 Yang, 2000, Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli, Science, 288, 874, 10.1126/science.288.5467.874 Nakhaei, 2012, IkappaB kinase epsilon-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis, J. Virol., 86, 726, 10.1128/JVI.05989-11 Franklin, 2007, Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis, Biochem. J., 405, 115, 10.1042/BJ20061576 Krumschnabel, 2009, The enigma of caspase-2: the laymen's view, Cell Death Differ., 16, 195, 10.1038/cdd.2008.170 Guo, 2002, Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria, J. Biol. Chem., 277, 13430, 10.1074/jbc.M108029200 Slee, 2000, Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release, Cell Death Differ., 7, 556, 10.1038/sj.cdd.4400689 Li, 1998, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, 94, 491, 10.1016/S0092-8674(00)81590-1 Holt, 2011, Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents, Oncol. Rep., 25, 1177 Carter, 2011, XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML, Apoptosis, 16, 67, 10.1007/s10495-010-0545-1 Carter, 2006, Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells, Blood, 107, 1555, 10.1182/blood-2004-12-4704 Sah, 2006, Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells, Int. J. Radiat. Oncol. Biol. Phys., 66, 852, 10.1016/j.ijrobp.2006.06.049 Capalbo, 2010, Radiation-induced survivin nuclear accumulation is linked to DNA damage repair, Int. J. Radiat. Oncol. Biol. Phys., 77, 226, 10.1016/j.ijrobp.2009.12.001 Rodel, 2012, The role of survivin for radiation oncology: moving beyond apoptosis inhibition, Curr. Med. Chem., 18, 191, 10.2174/092986711794088362 Vermeulen, 2007, Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells, Radiat. Res., 168, 683, 10.1667/RR1057R.1 Shih, 2005, Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells, Cancer Res., 65, 9194, 10.1158/0008-5472.CAN-05-2387 Rao, 2005, Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage, Mol. Cell. Biol., 25, 8925, 10.1128/MCB.25.20.8925-8937.2005 Rahden-Staron, 2003, Defective Brca2 influences topoisomerase I activity in mammalian cells, Acta Biochim. Pol., 50, 139, 10.18388/abp.2003_3721 Marple, 2006, Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination, Mutat. Res., 602, 110, 10.1016/j.mrfmmm.2006.08.005 James, 2009, Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature, Anticancer Drugs, 20, 634, 10.1097/CAD.0b013e32832b511e Nakamura, 2011, Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair, PLoS Genet., 6, e1000828, 10.1371/journal.pgen.1000828 Sonoda, 2007, Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair, DNA Repair (Amst), 6, 280, 10.1016/j.dnarep.2006.10.025 Wang, 2006, The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining, Oncogene, 25, 1980, 10.1038/sj.onc.1209212 Nomura, 2007, Human Mus81 and FANCB independently contribute to repair of DNA damage during replication, Genes Cells, 12, 1111, 10.1111/j.1365-2443.2007.01124.x Wang, 2010, PTIP promotes DNA double-strand break repair through homologous recombination, Genes Cells, 15, 243, 10.1111/j.1365-2443.2009.01379.x Ambrosini, 2008, The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner, Cancer Res., 68, 2312, 10.1158/0008-5472.CAN-07-2395 Godthelp, 2002, Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability, Nucleic Acids Res., 30, 2172, 10.1093/nar/30.10.2172 Saberi, 2008, The 9-1-1 DNA clamp is required for immunoglobulin gene conversion, Mol. Cell. Biol., 28, 6113, 10.1128/MCB.00156-08 Shiomi, 2007, Human RAD18 is involved in S phase-specific single-strand break repair without PCNA monoubiquitination, Nucleic Acids Res., 35, e9, 10.1093/nar/gkl979 Huang, 2009, RAD18 transmits DNA damage signalling to elicit homologous recombination repair, Nat. Cell Biol., 11, 592, 10.1038/ncb1865 Saberi, 2007, RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair, Mol. Cell. Biol., 27, 2562, 10.1128/MCB.01243-06 Sharma, 2007, Human RECQ1 is a DNA damage responsive protein required for genotoxic stress resistance and suppression of sister chromatid exchanges, PLoS One, 2, e1297, 10.1371/journal.pone.0001297 Hu, 2009, Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment, Mol. Biol. Cell, 20, 114, 10.1091/mbc.E08-06-0565 Wang, 2009, Human RIF1 encodes an anti-apoptotic factor required for DNA repair, Carcinogenesis, 30, 1314, 10.1093/carcin/bgp136 Hinz, 2003, Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3, Carcinogenesis, 24, 249, 10.1093/carcin/24.2.249 Caldecott, 1991, Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents, Mutat. Res., 255, 111, 10.1016/0921-8777(91)90046-R Thacker, 1990, DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia–telangiectasia cells, Mutat. Res., 235, 49, 10.1016/0921-8777(90)90057-C Lebel, 1998, A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity, Proc. Natl. Acad. Sci. U. S. A., 95, 13097, 10.1073/pnas.95.22.13097 Poot, 1999, Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase, Hum. Genet., 104, 10, 10.1007/s004390050903 Pichierri, 2000, Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage, Mutat. Res., 456, 45, 10.1016/S0027-5107(00)00109-3 Rodriguez, 2008, Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of Mre11, Clin. Cancer Res., 14, 5476, 10.1158/1078-0432.CCR-08-0274 Johnson, 1999, The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: two new complementation groups of etoposide sensitive mutants, Mutat. Res., 435, 271, 10.1016/S0921-8777(99)00055-5